Cardiff Oncology Q3 EPS $(0.12) Beats $(0.15) Estimate, Sales $171.000K Beat $67.857K Estimate
Benzinga Newsdesk 7 hours ago
NewsEarningsEarnings Beats
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 29.41 percent increase over losses of $(0.17) per share from
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 29.41 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $171.000 thousand which beat the analyst consensus estimate of $67.857 thousand by 152.00 percent. This is a 42.50 percent increase over sales of $120.000 thousand the same period last year.